Diseased PBMC and BMMC samples are occasionally collected at a different date from the initial sample utilized to establish blast percentages. Therefore, DLS is unable to guarantee blast percentages in diseased samples. However, for AML and multiple myeloma BMMCs, DLS performs flow cytometry following cryopreservation to characterize blast percentages, and these results are available to aid in sample selection.
NEW White Paper - Companion Diagnostic Development: An Overview
Primary Human Mast Cells are Now Available
Discovery's Contribution to AR Microscopy Study Featured in Nature
Learn More about Discovery's AI-Annotated FFPE Tissues and DiscoverAI Tissue Analysis
NEW Blog Post - Improving Pathology Precision in Oncology: How AI Reduces Variability in Tumor Percent Assignments
NEW Video - Advancing Oligo Therapeutics: Gene Knockdown Studies in Human Hepatocytes
NEW White Paper - Companion Diagnostic Development: An Overview
Primary Human Mast Cells are Now Available
Discovery's Contribution to AR Microscopy Study Featured in Nature
Learn More about Discovery's AI-Annotated FFPE Tissues and DiscoverAI Tissue Analysis
NEW Blog Post - Improving Pathology Precision in Oncology: How AI Reduces Variability in Tumor Percent Assignments
NEW Video - Advancing Oligo Therapeutics: Gene Knockdown Studies in Human Hepatocytes